#IASO_Bio
LightNews LightNews
newsen.bsky.social
IASO Bio's FUCASO Shows Promising Real-World Data for Multiple Myeloma Treatment#China#Shanghai#CAR-T_therapy#IASO_Bio#FUCASO
IASO Bio's FUCASO Shows Promising Real-World Data for Multiple Myeloma Treatment
At the 2026 IMS Annual Meeting, IASO Bio unveiled significant real-world data for FUCASO, their CAR-T therapy, demonstrating high response rates in patients with severe plasma cell neoplasms.
third-news.com
September 27, 2026 at 3:23 AM
newsen.bsky.social
IASO Bio Reveals Groundbreaking Results for First-in-Human BCMA-Therapy in Multiple Myeloma#China#Shanghai#CAR-T_therapy#IASO_Bio#Myeloma_Treatment
IASO Bio Reveals Groundbreaking Results for First-in-Human BCMA-Therapy in Multiple Myeloma
IASO Bio presents promising initial results of IASO206, an innovative in vivo CAR-T therapy targeting BCMA for difficult-to-treat multiple myeloma patients. The data demonstrates an impressive response rate and manageable safety profile.
third-news.com
September 27, 2026 at 3:12 AM
newsen.bsky.social
Innovative Phase 1 Study of RD140 Showcases Promising Results in Treating Relapsed Multiple Myeloma#China#Shanghai#IASO_Bio#CAR-T#RD140
Innovative Phase 1 Study of RD140 Showcases Promising Results in Treating Relapsed Multiple Myeloma
RD140, a novel CAR-T therapy, exhibits remarkable efficacy in treating advanced multiple myeloma in initial clinical trials, showcasing a high response rate.
third-news.com
September 25, 2026 at 3:39 PM
newsen.bsky.social
Latest Findings from IASO Bio's FUMANBA-1 Study on CAR-T Cell Persistence and Disease Progression#China#Shanghai#IASO_Bio#CAR-T_Cells#FUCASO
Latest Findings from IASO Bio's FUMANBA-1 Study on CAR-T Cell Persistence and Disease Progression
Recent insights from IASO Bio's FUMANBA-1 study showcase the correlation between CAR-T cell persistence and extended disease control in multiple myeloma patients.
third-news.com
September 25, 2026 at 3:07 PM
newsen.bsky.social
IASO Bio Shares Promising Updates for CAR-T Therapy in Multiple Myeloma at 2025 ASH#China#Shanghai#CAR-T_therapy#Multiple_Myeloma#IASO_Bio
IASO Bio Shares Promising Updates for CAR-T Therapy in Multiple Myeloma at 2025 ASH
IASO Bio introduced new clinical results for their CAR-T therapy, Equecabtagene Autoleucel (Eque-cel), for high-risk multiple myeloma patients at ASH 2025.
third-news.com
December 8, 2025 at 2:07 AM
newsen.bsky.social
IASO Bio Showcases Impressive Three-Year Results of CAR-T Therapy for Multiple Myeloma at IMS 2025#China#Shanghai#CAR-T_therapy#IASO_Bio#FUCASO
IASO Bio Showcases Impressive Three-Year Results of CAR-T Therapy for Multiple Myeloma at IMS 2025
IASO Bio revealed notable three-year follow-up findings for its CAR-T therapy, Fucaso, for treating multiple myeloma at the 2025 IMS Annual Meeting, showing strong long-term efficacy.
third-news.com
September 19, 2025 at 1:51 AM
newsen.bsky.social
IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients#China#Shanghai#IASO_Bio#CAR-T#GPRC5D
IASO Bio's Innovative CAR-T Therapy Shows Promise for Multiple Myeloma Patients
IASO Biotherapeutics announces significant results for RD118, its anti-GPRC5D CAR-T therapy, offering hope for multiple myeloma patients with few options left.
third-news.com
October 22, 2025 at 11:45 AM
newsen.bsky.social
IASO Bio's Groundbreaking CAR-T Therapy IASO208 Gets FDA IND Clearance, Paving Way for Innovative Cancer Treatments#United_States#CAR-T_therapy#Pleasanton#IASO_Bio#IASO208
IASO Bio's Groundbreaking CAR-T Therapy IASO208 Gets FDA IND Clearance, Paving Way for Innovative Cancer Treatments
IASO Bio's IASO208, a cutting-edge CAR-T therapy targeting B-cell non-Hodgkin lymphoma, receives FDA IND clearance, marking a significant milestone in oncology.
third-news.com
September 16, 2026 at 9:59 AM
newsen.bsky.social
IASO Biotechnology Enhances Global Position with MediSix Acquisition#China#Nanjing#IASO_Bio#Cell_Therapy#MediSix
IASO Biotechnology Enhances Global Position with MediSix Acquisition
IASO Biotechnology has successfully acquired MediSix Therapeutics, strengthening its global reach and enhancing cell therapy innovations.
third-news.com
August 13, 2026 at 11:19 AM
newsen.bsky.social
IASO Bio Partners with Instituto Butantan to Revolutionize Hematological Cancer Therapy in Brazil#Brazil#São_Paulo#CAR-T_therapy#IASO_Bio#Butantan_Institute
IASO Bio Partners with Instituto Butantan to Revolutionize Hematological Cancer Therapy in Brazil
IASO Bio has teamed up with Instituto Butantan to develop an affordable CAR-T therapy for hematological cancer in Brazil, enhancing patient access.
third-news.com
April 10, 2026 at 1:48 PM
newsen.bsky.social
IASO Bio Secures PMDA Approval for CAR-T Therapy Trial Against Multiple Myeloma#Japan#Tokyo#CAR-T_therapy#Multiple_Myeloma#IASO_Bio
IASO Bio Secures PMDA Approval for CAR-T Therapy Trial Against Multiple Myeloma
IASO Bio has gained official clearance from Japan's PMDA for clinical trials of Equecabtagene Autoleucel, targeting multiple myeloma patients. This marks a significant step in cancer treatment innovation.
third-news.com
March 24, 2026 at 8:53 AM
newsen.bsky.social
IASO Biotechnology's Fucaso Therapy Receives BLA Approval for Advanced Multiple Myeloma Treatment#China#Hong_Kong#CAR-T_therapy#IASO_Bio#FUCASO
IASO Biotechnology's Fucaso Therapy Receives BLA Approval for Advanced Multiple Myeloma Treatment
IASO Bio's Fucaso therapy, approved by Hong Kong's Department of Health, treats relapsed multiple myeloma. This marks a significant milestone for China-developed therapies.
third-news.com
November 27, 2025 at 5:47 AM
newsen.bsky.social
IASO Bio Teams Up with GC Cell to Enhance CAR-T Therapy Access in Korea#Nanjing#South_Korea#CAR-T_therapy#IASO_Bio#GC_Cell
IASO Bio Teams Up with GC Cell to Enhance CAR-T Therapy Access in Korea
IASO Bio has partnered with GC Cell to launch the CAR-T therapy Fucaso in Korea, aiming to improve treatment options for multiple myeloma patients. The collaboration seeks to enhance accessibility through competitive pricing.
third-news.com
October 29, 2025 at 9:14 AM
newsen.bsky.social
IASO Bio to Showcase Innovative CAR-T Therapy Findings for MS at Major Conferences in 2025#USA#Baltimore#CAR-T_therapy#IASO_Bio#Equecabtagene
IASO Bio to Showcase Innovative CAR-T Therapy Findings for MS at Major Conferences in 2025
IASO Bio is set to present its groundbreaking anti-BCMA CAR-T cell therapy Equecabtagene Autoleucel for Multiple Sclerosis at the renowned ANA and ECTRIMS events in 2025.
third-news.com
September 12, 2025 at 7:50 AM
newsen.bsky.social
Breakthrough Efficacy of Equecabtagene Autoleucel Presented at EAN Congress for MS Treatment#China#Shanghai#Multiple_Sclerosis#IASO_Bio#Equecabtagene
Breakthrough Efficacy of Equecabtagene Autoleucel Presented at EAN Congress for MS Treatment
At the 11th EAN Congress, IASO Bio showcased promising results from a study on Equecabtagene Autoleucel, an innovative MS therapy, indicating significant improvements in patient conditions.
third-news.com
June 23, 2025 at 2:07 AM
newsen.bsky.social
IASO Bio Marks Significant Milestones with New R&D Center and Forum in Shanghai#China#Shanghai#IASO_Bio#Cell_Therapy#R&D_Center
IASO Bio Marks Significant Milestones with New R&D Center and Forum in Shanghai
IASO Biotherapeutics celebrates the inauguration of its Global R&D Center in Shanghai, emphasizing advancements in cell therapy and strategic partnerships for international commercialization.
third-news.com
May 21, 2025 at 1:19 AM
newsen.bsky.social
IASO Bio's Equecabtagene Autoleucel Receives Approval in Macau - A Milestone for Cell Therapies#China#CAR-T_therapy#Macao#IASO_Bio#Equecabtagene
IASO Bio's Equecabtagene Autoleucel Receives Approval in Macau - A Milestone for Cell Therapies
IASO Biotherapeutics celebrates the Macau approval of Equecabtagene Autoleucel, a groundbreaking CAR-T therapy for multiple myeloma patients.
third-news.com
March 28, 2025 at 5:00 AM
newsen.bsky.social
IASO Bio’s Equecabtagene Autoleucel Secures Regulatory Green Light in Hong Kong#China#Hong_Kong#CAR-T_therapy#IASO_Bio#FUCASO
IASO Bio’s Equecabtagene Autoleucel Secures Regulatory Green Light in Hong Kong
IASO Biotherapeutics has received acceptance for its New Drug Application for Equecabtagene Autoleucel, a CAR-T therapy for relapsed multiple myeloma, from Hong Kong health authorities.
third-news.com
February 14, 2025 at 2:40 PM
newsen.bsky.social
IASO Bio's New Drug Application Acceptance Marks Milestone for FUCASO in Singapore#Singapore#IASO_Bio#Equecabtagene#FUCASO
IASO Bio's New Drug Application Acceptance Marks Milestone for FUCASO in Singapore
IASO Bio's Equecabtagene Autoleucel (FUCASO) receives NDA acceptance from Singapore's HSA, marking a significant step in CAR-T therapy expansion.
third-news.com
January 29, 2025 at 12:38 PM
newsen.bsky.social
New Insights on CAR T-Cell Therapy Effectiveness: Study by IASO Bio at 2024 ASH Annual Meeting#China#Shanghai#Multiple_Myeloma#IASO_Bio#CAR_T-Cell
New Insights on CAR T-Cell Therapy Effectiveness: Study by IASO Bio at 2024 ASH Annual Meeting
IASO Bio unveils key study findings on CAR T-Cell persistence in treating relapsed/refractory multiple myeloma at the 2024 ASH meeting, emphasizing implications for future therapies.
third-news.com
December 10, 2024 at 2:04 AM